Today's Post-Market Laggard Is Jazz Pharmaceuticals (JAZZ)
Trade-Ideas LLC identified
(
) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Jazz Pharmaceuticals as such a stock due to the following factors:
- JAZZ has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $95.4 million.
- JAZZ is down 3.6% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in JAZZ with the Ticky from Trade-Ideas. See the FREE profile for JAZZ NOW at Trade-Ideas
More details on JAZZ:
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. JAZZ has a PE ratio of 33. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.
The average volume for Jazz Pharmaceuticals has been 700,900 shares per day over the past 30 days. Jazz has a market cap of $8.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.81 and a short float of 6.1% with 3.61 days to cover. Shares are down 12.9% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Jazz Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 7.1%. Since the same quarter one year prior, revenues rose by 14.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 101.8% when compared to the same quarter one year prior, rising from $43.66 million to $88.11 million.
- Net operating cash flow has significantly increased by 87.61% to $140.57 million when compared to the same quarter last year. In addition, JAZZ PHARMACEUTICALS PLC has also vastly surpassed the industry average cash flow growth rate of -17.22%.
- The gross profit margin for JAZZ PHARMACEUTICALS PLC is currently very high, coming in at 94.17%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 26.40% trails the industry average.
- JAZZ's debt-to-equity ratio of 0.94 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Even though the debt-to-equity ratio shows mixed results, the company's quick ratio of 4.95 is very high and demonstrates very strong liquidity.
- You can view the full Jazz Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.